Dr. Plimack On Frontline Pembrolizumab For Urothelial Carcinoma

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

Dr. Plimack on KEYNOTE-045 Trial for Pembrolizumab in Urothelial Carcinoma

Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer

Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma

Dr. Plimack on a Phase Ib Study of Pembrolizumab in Bladder Cancer

Targeted Oncology

Pembrolizumab in Urothelial Cancer

Targeted Oncology

Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

Dr. Plimack on the Growth of Immunotherapy in Bladder Cancer

Dr. Plimack on Frontline Checkpoint Inhibitors in Bladder Cancer

Results for Pembrolizumab as a First-Line Therapy for Advanced Urothelial Carcinoma

Targeted Oncology

Analyzing Frontline Options for Patients With Bladder Cancer

Targeted Oncology

Dr. Elizabeth Plimack on Immunotherapy Potential in Bladder Cancer

Exploring the Combination of Epacadostat and Pembrolizumab in Urothelial Carcinoma

Targeted Oncology

Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer

Dr. Garcia on FDA Approval of Pembrolizumab in Bladder Cancer

Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer

Is pembrolizumab alone sufficient to treat bladder cancer?

Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer

Targeted Oncology

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer